Stockscreener 앱 받기
2.95
3.91%
-0.12
Casi Pharmaceuticals Inc 주식(CASI)의 최신 뉴스
CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection of Kidney Transplant - Marketscreener.com
CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA - TipRanks
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - The Eastern Progress Online
CASI Pharmaceuticals Faces Evomela® License Termination Dispute - TipRanks
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34% - Simply Wall St
CASI Pharmaceuticals Insider Ups Holding By 65% During Year - Simply Wall St
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - AccessWire
CASI Pharma Q3 Revenue Jumps 96% QoQ to $7.8M Despite Wider Losses, Advances Pipeline | CASI Stock News - StockTitan
CASI Pharmaceuticals Inc (CASI) Quarterly 10-Q Report - Quartzy
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - GuruFocus.com
(CASI) Proactive Strategies - Stock Traders Daily
CASI Pharmaceuticals gets China nod for ITP treatment trial - Investing.com
CASICASI Pharmaceuticals, Inc. Ordinary Shares Latest Stock News & Market Updates - StockTitan
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - AccessWire
CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Update - MarketBeat
Objective long/short (CASI) Report - Stock Traders Daily
Renaissance Technologies LLC Acquires 4,000 Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Defense World
(CASI) Trading Report - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200 Day Moving Average of $4.67 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average of $4.67 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week - Yahoo Finance
CASI Pharmaceuticals (NASDAQ:CASI) pulls back 22% this week, but still delivers shareholders solid 129% return over 1 year - Simply Wall St
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Passes Above 200 Day Moving Average of $4.60 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above Two Hundred Day Moving Average of $4.60 - Defense World
Tumor Necrosis Factor Inhibitor Drugs Market Insights Discussed Regarding Trends and Forecast Report 2024-2033 - WhaTech
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above 200 Day Moving Average of $4.57 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above 200-Day Moving Average of $4.57 - MarketBeat
(CASI) Investment Report - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above 200 Day Moving Average of $4.48 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above 200-Day Moving Average of $4.48 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Passes Above 200-Day Moving Average of $4.46 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above Two Hundred Day Moving Average of $4.46 - MarketBeat
Short Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 6.9% - Defense World
(CASI) Technical Pivots with Risk Controls - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Announces Quarterly Earnings Results - Defense World
Idg Accel China Growth Fund Iii L.p. Net Worth (2024) - GuruFocus.com
CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 - MSN
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PR Newswire
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above 200 Day Moving Average of $4.47 - MarketBeat
0.76%
0.69%
자본화:
|
볼륨(24시간):